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CHAPTER 1 
INTRODUCTION 
DEMENTIA 
 
 Dementia is not a disease in itself but is a general term used to describe a variety of 
diseases and conditions that emerge when nerve cells in the brain die or no longer function 
normally. This thereby causes death or malfunction of these nerve cells (neurons), leading to 
changes in one’s memory, behavior and cognitive abilities [1].  According to the Diagnostic and 
Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) [2], a patient has dementia 
when they present a decline in memory and at least one of the following symptoms: 
 1) Ability to generate coherent speech or understand spoken or written language. 
2) Ability to recognize or identify objects, assuming intact sensory function.  
3) Ability to execute motor activities, assuming intact motor abilities and sensory function and 
comprehension of the required task.  
4) Ability to think abstractly, make sound judgments and plan and carry out complex tasks.  
1.1.1    TYPES OF DEMENTIA 
 
 There are different types of dementia, categorized by their symptoms and brain 
abnormalities [1][2][3]. 
a. Alzheimer’s disease: This is the most common form of dementia.  
Early symptoms: Difficulty remembering names and current events; apathy and depression  
Late symptoms: Impaired judgment, disorientation, confusion, behavior changes and 
difficulty speaking, swallowing and walking. 
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Brain abnormalities: Deposition of beta-amyloid (plaques) and twisted strands of the protein 
tau (tangles) along with proof of nerve cell damage and death in the brain. 
b. Vascular dementia: This form of dementia was formerly known as multi-infarct or post-
stroke dementia (dementia secondary to stroke). 
Symptoms: Impaired judgment or ability to make plans  
Brain abnormality: Localized brain injury leading to microscopic bleeding and blockage of 
blood vessels. 
c. Dementia with Lewy bodies(DLB): Lewy bodies are abnormal clumps of the protein called 
alpha-synuclein. 
Symptoms: Vivid hallucinations, sleep disturbances in additions to the symptoms seen in 
Alzheimer’s disease. 
Brain abnormality: Deposition of alpha-synuclein in the cerebal cortex of the brain. 
d. Mixed dementia: As its name goes, it’s symptoms include a combination those seen in 
Alzhiemer’s disease, vascular dementia and DLB. 
Brain abnormality : There’s more of beta amyloid deposition and injury to the brain seen. 
e. Parkinson’s disease: Presentation is similar to that of DLB or Alzheimer’s disease. 
Symptoms: Difficulty moving around. 
Brain abnormality: Alpha-synuclein is deposited in a deep area of the brain called the 
substantia nigra. This deposition is believed to destroy nerve cells that produce dopamine 
thereby resulting in Parkinson’s disease. 
f. Frontotemporal lobar degeneration (FTLD): There are subtypes of FTLD such as as 
behavioral variant FTLD, primary progressive aphasia, Pick’s disease and progressive 
supranuclear palsy. 
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Symptoms: Difficulty with languages, altered behavior and personality 
Brain abnormality: There is no distinct abnormality seen, however the neurons on the front 
and side regions of the brain seem to be affected. 
g. Creutzfeldt-Jakob disease: There is a variant form of this disease which results from the 
feeding on products from cattle infected with the mad cow disease. This disease is rapidly 
fatal. 
Symptoms: Memory and coordination impairment, altered behavior. 
Brain abnormality: Malfunction of protein of the brain. This is as a result of prions 
(misfolded proteins) causes other proteins of the brain to misfold. 
f.   Normal pressure hydrocephalus: This type of dementia can be corrected by the insertion of    
a shunt in the brain to drain fluids. 
     Symptoms: Urinary incontinence, loss of memory and impaired coordination 
      Brain abnormality: Accumulation of fluid in the brain. 
1.1 ALZHIEMER’S DISEASE 
 
 Alzheimer’s disease (AD) accounts for 50 to 70 % of dementia presentations. It 
was initially identified and brought to light in 1906  by Aloysius ‘Alois’ Alzheimer, a 
German psychiatrist and neuropathologist  as amyloid plaques (Aβ) and neurofibrillary 
tangles (NFTs) from a 51-year old patient named Auguste Deter. This patient presented 
impaired mental function with significant cognitive decline [4]. AD is the sixth leading 
cause of death in the United States and the fifth leading cause of death in people over the 
age of 65, as determined by the Centers for Disease Control and Prevention (CDC) [5]. 
The risk of developing AD increases exponentially with age. This disease has since been 
diagnosed in more than 5.1 million people in the United States alone. In 2015, the direct 
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costs to the United States for caring Alzheimer's patients estimated at total of $226 
billion, with half of the costs borne by Medicare. People 65 years of age and older with 
Alzheimer’s and other dementia spend three times higher on average per-person 
Medicare expenses than for seniors without dementia. The Medicaid payments are 19 
times higher. Approximately one in every five Medicare dollars is spent on people with 
Alzheimer's and other dementias. In 2050, it will be one in every three dollars [6]. There 
are two forms of AD; early onset (EOAD) and the late onset also known as sporadic AD 
(LOAD/SAD). The late onset AD accounts for about 87% of the cases and early onset 
accounts for about 13% of cases. It has stimulated several hypothesis as its possible cause 
(although actual process of development is still yet to be understood). It is characterized 
by a significant deficit of hippocampal neurons which leads to decrease in cognition, 
memory loss ultimately, dementia. There is the cholinergic, tau and amyloid hypothesis, 
in our study we explored the amyloid hypothesis [7]. 
 
The Cholinergic hypothesis: 
    It has been discovered that AD patients have low concentrations of acetylcholine.      
Acetylcholine is a neurotransmitter that is metabolized by an enzyme ( a serine protease) called 
acetylcholine esterase in the central nervous system (CNS) into acetate and choline as seen in 
figure 1 below[8]. This chemical serves as a neuro-modulator in the CNS and is located in the 
pre-ganglionic and parasympathetic neurons. It is also the neurotransmitter in the sweat glands 
and piloerector muscles of the sympathetic autonomic nervous system. 
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Figure 1: Breaking down of acetylcholine by acetylcholine esterase. 
 
        The brain of mammals contains two major forms of cholinesterases: acetylcholinesterase 
(AChE) and butyrylcholinesterase (BuChE). The two forms differ genetically, structurally, and 
for their kinetics. Butyrylcholine is not a physiological substrate in mammalian brain, which 
makes the function of of difficult interpretation. In human brain, BuChE is found in neurons and 
glial cells, as well as in neuritic plaques and tangles in AD patients. Whereas, AChE activity 
decreases progressively in the brain of AD patients, BuChE activity shows some increase [9]. 
The Tau Hypothes 
         Tau is a microtubule-associated protein (MAP) required for stabilizing microtubules 
and neurite outgrowth [10]. Normal Tau interacts with tubulin, facilitates its assembly into 
microtubules and stabilizes their structure [11]. Tau-based neurofibrillary pathology is found 
in more than 20 neurodegenerative diseases. Phosphorylation of Tau within the microtubule 
binding repeats (R) is necessary for appropriate neurite outgrowth. The ratio of 3R and 4R 
Tau isoforms is generally 1:1 in the adult brain, but deviations from this ratio may cause 
Tauopathies (Tau pathologies) [12]. Hyperphosphorylated Tau spontaneously aggregates into 
paired helical filaments (PHF), which can subsequently form NFTs. In AD, 
hyperphosphorylated Tau accumulates, prompting its dissociation from microtubules, thus 
leading to their destabilization and the disruption of neuronal transport. 
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The Amyloid Hypothesis: 
        One of the hallmarks of AD is the accumulation of amyloid plaques between nerve cells 
(neurons) in the brain. The amyloid hypothesis indicates that is accumulation leads to a chain of 
events that culminate the AD pathology. These events damage synapses and neurons thereby 
producing neuroinflammation, neurodegeneration, loss of synapses, formation of neurofibrillary 
tangles and aggregation of beta amyloid (Figure 1). Amyloid are protein fragments that the body 
produces normally. Beta amyloid is a protein fragment cleaved from an amyloid precursor 
protein  (APP), which are involved in neuro-genesis and neural development. In a healthy brain, 
these protein fragments are broken down and eliminated [13]. In AD, the fragments accumulate 
to form hard, insoluble plaques.   
        The cleavage of APP takes place at the N-terminal of a beta amyloid sequence, this 
gives rise to a C -terminal APP fragment, C99 and a large secreted N-terminal product called 
sAPP-β. The sAPP-β is a soluble fragment. C99 is further cleaved by gamma secretase 
(containing catalytic subunits; presenilin, Aph-1, Nicastrin, and Pen-2 protein) forming a beta 
amyloid fragment and an APP intracellular domain (AICD) [14]. The end result is beta 
amyloid (Aβ), a peptide of amino acids ranging from 36 to 43, the main component of 
amyloid plaques. Aβ40 is soluble and turns out to be the most abundant species accounting for 
90% of the total Aβ peptide in normal brains and AD brains. Aβ42 is the primarily abundant 
in patients presenting with AD. Aβ42 possess 2 hydrophobic ends therefore this species has a 
very high propensity for clustering or aggregating. It forms toxic oligomers which facilitate 
the formation of plaques [15]. The accumulation of Aβ42 is highly due to mutations in 
presenilin genes present in vertebrates (which encode for PS-1 and PS-2) which are key 
catalytic subunits of gamma secretase intramembrane protease complex (Figure 3). The 
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mutations in presenilin genes and APP play a major role in the accumulation of Aβ42 which 
subsequently leads to the formation of fibrils and eventually neurotoxity or cerebral beta 
amyloidosis [16]. These mutations predominantly accounts for the presentation of early onset 
AD which is referred to as familial AD. In AD patients the amyloid accumulation drives the 
deposition of the plaques because it happens to be the main component protein of the plaque. 
This subsequently causes formation of neurofibrillary tangles, neuronal loss, vascular damage 
and dementia. The severity of AD is directly proportional to the amount of amyloid plaque 
accumulated [17]. The aforementioned process describes the amyloidogenic processing of 
APP. It should be noted that physiologically beta amyloid peptides are generated at low 
concentrations and that a significant amount of APP is processed via the non-amyloidogenic 
pathway that involves cleavage of APP by alpha secretase. 
         Now the alpha site of APP is cleaved by alpha secretase (comprising of members of the 
disintegrin and metalloproteinase; ADAM family) producing C83, an α-secretase-generated C-
terminal APP fragment (α-CTF) and N-terminal portion of APP (soluble APP-α; sAPP-α) [18]. 
The fragment, α-CTF undergoes further processing by the γ-secretase complex to generate 
AICD and p3 peptides. sAPP-α is found to be neurotrophic and neuroprotective properties [19]. 
Studies have revealed that the suppression of sAPP-α by conditions such as oxidative stress, 
abnormal lipid metabolism, abnormal glucose metabolism, physical inactivity, and cerebral 
hypoperfusion can lead to sporadic AD (SAD). sAPP-α is highly being considered for potential 
therapeutic properties [20]. It is unquestionable that the AD pathology is mostly due to the 
accumulation of Aβ and inhibition or suppression of sAPP-α .rather than altered expression of 
APP or its products, causes AD pathology. 
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Figure 2:  Generation of Aβ42 
 
Epsilon 4 allele of the apolipoprotein E gene (APOE ε4): 
          Apolipoprotein E is a class of apolipoprotein that primarily break down and transport 
triglycerides, cholesterol and beta amyloid. It is a polymorphic gene with three alleles; ε2, ε3 
and ε4. The allele; ε2 is protective against AD but may increase or decrease risk of an 
atherosclerosis diagnosis but it facilitates the metabolism of beta amyloid. The allele, ε3 is 
considered the neutral allele of ApoE while the ε4 form is linked with a high risk of getting AD 
[21].  ApoE-ε4 has been linked to late onset AD [17]. The allele, ε4 significantly increases the 
chances of sporadic AD by 3 fold in heterozygotes and by 15 fold in homozygotes [22]. In the 
presence of ApoE-ε4, there is a gain in toxic function due to inefficient metabolism of beta 
amyloid. Therefore, an accumulation of beta amyloid which leads to a cascade of damaging 
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processes which include decreased lipid metabolism, decrease in synaptic function , neuronal 
toxicity, atrophy of the brain and increased aggregation of beta amyloid peptides [23]. 
1.2.1 SYMPTOMS OF ALZHEIMER’S DISEASE 
 
        Clinical experts have categorized the symptoms of AD to fall under mild cognitive 
impairments. This includes significant attention deficits, decline in learning and memory, 
decreased executive function, declined speed in processing information, and semantic language. 
[24]. 
 
1.2.2 DIAGNOSIS OF ALZHEIMER’S DISEASE 
 
        Innovative early diagnostic tests have been developed to detect AD before symptoms 
begin to     appear. One such test involves the analysis of cerebrospinal fluid for beta-amyloid or 
tau proteins,
 
[25] both total tau protein and phosphorylated tau181P protein concentrations.
 
Searching for these proteins using a spinal tap can predict the onset of Alzheimer's with 
a sensitivity of between 94% and 100% [26][27]. When used in conjunction with 
existing neuroimaging techniques, doctors can identify people with significant memory loss 
who are already developing the disease [28]. Alzheimer's disease is usually diagnosed based on 
the person's medical history, history from relatives, and behavioural observations. The presence 
of characteristic neurological and neuropsychological features and the absence of alternative 
conditions is supportive [29][30]. Advanced medical imaging with computed tomography (CT) 
or magnetic resonance imaging (MRI), and with single-photon emission computed 
tomography (SPECT) or positron emission tomography (PET) can be used to help exclude other 
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cerebral pathology or subtypes of dementia [31]. Moreover, it may predict conversion 
from prodromal stages (mild cognitive impairment) to Alzheimer's disease [32]. 
1.2.3 TREATMENT OF ALZHEIMER’S DISEASE 
 
      There is currently no cure for AD. The interventions are palliative in nature and cover three  
categories of management of AD; psychosocial, pharmaceutical and caregiving. 
        Psychosocial: This intervention has insufficient data to proof its efficaciousness. It targets more   
dementia than AD and it is administered as an adjunct to pharmaceutical intervention [33]. 
Psychosocial options include emotion-oriented interventions, behavioral interventions and 
cognitive-oriented treatments [34]. 
      Pharmaceutical: This method of managing AD borders on two approaches; inhibiting acetyl-
cholinerase and N-Methyl-D-aspartate (NMDA). Four medications have been developed that 
inhibit acetyl-cholinerase, they include tacrine, rivastigmine,galantamine and donepezil[35]. 
Unfortunately, none of the medical treatments listed can cure AD. In fact, the improvement due 
to medical intervention are mild to moderate and last for 6 months to 1 year. 
        Nutritional: There has been several studies conducted showing the effect of bioactive 
components of food on AD; omega-3 fatty acids, antioxidants or B vitamins, and dietary 
patterns (Mediterranean diet) have demonstrated protective effects on age related chronic 
diseases [36]. Cassia Obtusifolia, a botanical that has been traditional used to treat inflammatory 
conditions and diseases of the liver and eye is currently being explored for neuro-protection in 
AD [37]. It’s proposed mechanism of action in treating or preventing AD is through the 
inhibition of  acetylcholinesterase (AChE), butyrylcholinesterase (BChE), and β-site amyloid 
precursor protein (APP) cleaving enzyme 1 (BACE1) enzyme activity. There is also the 
possibility of treatment of AD with antioxidants due to the damaging effects of oxidative stress 
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on nerve cells and synapses. The question of whether or not antioxidants play a role in treating 
AD due to the effect of reactive oxygen species (ROS) which can subsequently lead to oxidative 
stress is still being explored. The presence of oxidative stress can cause high concentrations of 
protein oxidation, protein nitration, glycoloxidation and lipid peroxidation and the hallmark of 
AD; accumulation of Aβ [38]. There is justification in experimenting on the effect of nutrition 
high in antioxidants on AD. 
 
       1.3   NUTRITION AND ALZHEIMER’S DISEASE 
 
        Nutrition plays a role in the presentation of AD. Extensive studies have shown that 
supplementation of the diet with antioxidant, B vitamins, polyphenols and polyunsaturated fatty 
acids and increase in the ingestion of fish, fruits, vegetables, coffee and light to moderate 
alcohol not only help treat AD but also reduce the risk of getting this disease, figure 3 [39].  
 
       
Figure 3:  Nutrition 
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        Foods and beverages that influence the incidence of AD. Fish, vegetables, fruits, coffee, and light-to-    
moderate   alcohol intake are reported to reduce AD incidence. Milk and tea are reported to 
influencecognition, but their influence on AD is not clear. 
 
 
         It is postulated that there is a correlation between the development of AD and oxidative 
stress. The generation of Aβ could actually be protective in hiding sources of free radicals. The 
accumulation of the Aβ as indicated earlier will induce AD as a result of insufficient or 
inefficient clearing. Aβ accumulation can interfere with the normal electron flow through the 
respiratory chain by binding to mitochondrial membranes and interacting with heme. This 
subsequently leads to the production of reactive oxygen species (ROS) and diminished 
mitochondrial energy metabolism.  This could justify the hypometabolism observed in patients 
with AD [40]. Data collected from studies conducted with flavonoid and non-flavonoid 
polyphenols have show promise in neutralizing excess ROS thereby suppressing their damaging 
effects.  
         Although there is limited data on the mechanism of action of antioxidants in AD, 
neuronal protection and potent scavenging of singlet oxygen, superoxide anions, hydroxyl 
radical and peroxyl radicals have been shown with the ingestion of epigallolcatechin (EGCG), 
resesveratrol and curcumin. The scientist, Schroeder demonstrated the effect of EGCG on the 
integrity of neuronal function on rat models and discovered selective protection of the rats 
cultured cerebullar granule neurons from oxidative stress [41]. EGCG has also shown protection 
from toxicity resulting from beta  amyloid precursor protein (APP), 3-hydroxykynurenine, or 6-
hydroxydopamine (6-OHDA) in SH-SY5Y human neuroblastoma cells [42]. Resveratrol 
 (trans-3,4′,5-trihydroxystilbene) is the key non-flavonoid polyphenol that can be extracted from 
grapes and found in red wine. It has anti-inflammatory, anti-carcinogenic and antioxidant 
activities [43]. Beta amyloid induced intracellular accumulation of reactive oxygen species was 
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attenuated by resveratrol [44]. In vivo studies have also reported attenuation of the degeneration 
of neurons in the hippocampus of the inducible p25 transgenic mouse model of AD and 
tauopathy by reseveratrol [45]. 
  1.3.1   CURCUMIN 
 
        Curcumin (diferuloylmethane) is a popular Asian spice is derived from Curcuma longa, 
turmeric. Over many years in has been utilized medicinally as a remedy for wound healing, 
inflammation and even as an anticarcinogen [46]. Epidemiological studies have revealed 
correlation between cognitive function and the intake of curcumin. One of these studies pulled a 
total of 1010 Asians between 60 and 93 years of age and subjected them to a standard test, 
MMSE that measures cognition. The subjects were placed into  groups  that consumed curry 
less frequently (less than once a month), rarely consumed curry and the consumed curry more 
often (more than once a month). The result of the study showed higher MMSE score for the 
group that consumed curry more often compared to those you either eat less or never eat curry 
[47]. Extensive research have shown that curcumin acts as an antioxidant, playing a major role 
in combating oxidative stress and health conditions related to oxidative stress like diabetes, 
obesity, cardiovascular disease and AD. It has shown to be a potent scavenger of different 
reactive oxygen species; like superoxide anion radicals, hydroxyl radicals [48], and nitrogen 
dioxide radicals [49][50]. It has been theorized that curcumin stimulates the activation of stress 
sensitive kinases in fructose fed rats by inhibiting phosphorylation of the kinases, thereby 
preventing cell damage [51].  A summary of the various revealed mechanisms of action of 
curcumin is displayed in figure 4. Studies conducted on cultured neuroblastoma cells focused on 
the effect of curcumin on the in vitro expression of PS1 and the enzyme glycogen synthase 
kinase-3, GSK-3β. GSK-3β presentation has been linked to the development of AD and 
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presenilin-1 has been identified as its substrate. Curcumin was reported to be successful in 
blocking the stimulation of presenilin-1 activity by GSK-3β, thereby reducing the production of 
beta amyloid peptides [52]. In addition, studies conducted at UCLA revealed that curcumin 
facilitates the metabolism or clearance of beta amyloid plaques in AD by macrophages [53].  
This justified our use of curcumin as a positive control in our research. 
 
 
Figure 4: Various mechanisms of action of curcumin 
 
1.4.1   OIL PALM PHENOLICS  
 
         Oil palm (Elaeis guineensis) is predominantly found in the tropics and contains a high 
concentration of water soluble phenolics. It is a high oil-producing tropical plant that appears to 
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have an effective anti-oxidative component to counter the oxidative stress exerted by high 
temperature and intense sunlight [54]. 
        An estimate of 85% of the world's palm oil consumed as food. This has lead to further research 
on the nutritional contents and benefits of this food product.  Oil Palm contains almost 50% 
saturated fatty acids (SFA). This percentage has presented in key area of research in 
determining its efficacy in relation to heart related diseases like coronary heart disease (CHD) 
risk.  The constituents of oil palm are 44% Palmitic acid (44%), the key SFA in palm and 
monounsaturated oleic acid (39%) and polyunsaturated linoleic acid (11%).  
         In addition to the fatty acid component of oil palm, there is also a phytochemical 
component. Oil palm contains carotenoids, tocopherols, tocotrienols, sterols, squalene, 
coenzyme Q10, phospholipids, and polyphenols. The presence of these phytochemicals ensures 
the quality and stability of the oil [55]. Apparently, all the phytochemical present in palm oil 
possess antioxidant properties. Oil Palm Phenolic (OPP) or the palm juice is the aqueous stream 
extracted from oil palm that is rich in phenolic antioxidants. The therapeutic effects of OPP on 
cardiovascular diseases, diabetes and cancers have been reported by Sambanthamurthi et al 
[56]. They concluded that OPP could be used as a dietary agent for prevention of many 
oxidative stress related chronic diseases, including neurodegenerative ailments. Plant phenolics 
are major antioxidants due to their high redox potential which causing them to be effective as 
reducing agents, hydrogen donors, singlet oxygen quenchers and chelators for metals. 
Antioxidants that accumulate in neuronal tissues are potential candidates for the prevention and 
treatment of neuronal disorders involving oxidative stress [57]. As a result of extensive research 
that has revealed the neuroprotective potential of OPP and the finding that the hallmark of 
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Alzheimer disease is neuroinflammation and oxidative stress impacting neurotoxicity, we test 
the impact of OPP on rats fed a high fat diet using curcumin as the positive control. 
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CHAPTER 2 
MATERIALS AND METHODS 
2.1 Animals and diets 
 
32 in-bred Brown Norway (BN) rats were obtained from the aged rodent colonies of the National 
Institute of Aging (Bethesda, MD). Since effects of estrogen on cholesterol metabolism might 
alter Aβ, we used male rats for this study. Upon arrival, 12 rats were 22 weeks old and 20 rats 
are 24 weeks old. They were assigned to 4 groups on a pseudo-random basis with the constraint 
that all diet groups had the same mean body weight. Four groups were named by their diets: 
control diet (n = 8), High fat diet (n=8), High fat with OPP (n=8) and High fat with Curcumin 
(n=8). The diet compositions are summarized in Table 1. Diets for four groups contained similar 
level of calorie. The purified diets were obtained in pelleted form from Dyets Inc. (Bethlehem, 
PA), and sufficient diet was obtained for the entire duration of the study. The diets were kept at -
20°C, and sufficient diet was removed weekly as needed and kept refrigerated at 4°C. Animals 
were fed ad libitum and had free access to tap water. 
Briefly, twice weekly food intake and weekly body weight were recorded to monitor health 
status (Table 2). Urine samples of each rat were collected once a month for urinary metabolomic 
profiling. Once a month, all rats were subjected to a five-day test of spatial learning/memory 
using Morris’s water maze. Monthly urine collections were carried out for a urinary metabolomic 
study. All procedures and protocols were in accordance with and ratified by the Animal 
Investigation Committee of Wayne State University. 
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Table 1:  Composition of purified diets 
Ingredient       isocaloric Control             High Fat (2% Cholesterol)                   High Fat+5% OPP                          High Fat+ 2%Curcumin 
      g/kg 
Casein                  140                                                                 140        140                       140 
L-Cystine              1.8                                                                 1.8                                           1.8                                                1.8 
Sucrose                 100                                                                 77.5                                         77.5                                               77.5 
Cornstarch            465.692                                                          465.692                                   415.692                                         445.692 
Dyetrose               155                                                                155                                           155                                                 155 
Soyabean oil         40                                                                  40                                             40                                                   40 
t-butylhydroquinone 0.008                                                         0.008                                        0.008                                              0.008 
Cellulose                  50                                                               50                                             50                                                   50 
Mineral                    35                                                               35                                              35                                                   35 
Mix#210050  
Vitamin                    10                                                               10                                               10                                                  10 
Mix#310025  
Choline Bitartrate     2.5                                                              2.5                                              2.5                                                 2.5 
Cholesterol               _               20                                               20                                                  20 
Cholic Acid              _                                                                 2.5                                               2.5                                                 2.5 
OPP                          _                                                                  _                                                 50                                                    _ 
Curcumin                  _                                                                 _                                                  _                                                     20 
Total(g)                    1000           1000         1000              1000 
                                                                                                                
Diets were prepared and pelleted by Dyets Inc. (Bethlehem, PA). 
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Table 2: Study timeline based on the overall study 
Procedures        Frequency of Measurement   
Body weight, diet intake, water intake     Twice weekly (Week 1-6) 
Urine collection        Once weekly (Week 2,4,6) 
Blood and tissue collection                               End of study  (Week 6)___   
 
2.2 Spatial Learning Test 
 A Morris Water Maze test (MWM) was conducted to examine spatial learning and 
memory. Rats were tested in a circular pool, 60 inches in diameter and 30 inches deep, filled 
with 10 inches of water made opaque by the addition of a non-toxic dye and maintained at 24-
25o C. The swimming pool was placed in a room surrounded by fixed spatial cues such as 
posters, floor lamp and desk. The rats were trained to locate the hidden escape platform 
submerged in the water. Latencies for rats to find the platform (sec) were analyzed as a measure 
of spatial learning. The Rats were given 3 trials/day for 5 consecutive days. Rats were allowed 
90 s to swim around the pool and find the hidden platform. If the rat did not find the platform 
within this time, it was gently rescued from the water and placed on the platform. Each trial was 
separated by 45 min. The platform was always located in the same fixed spot during training and 
the starting point also remained the same among the trials for each rat. All trials were recorded 
by a video camera mounted above the pool and the behavioral measures were acquired by a 
computerized video-tracking system (EthoVision 2.0, Noldus Information Technology, 
Leesburg, VA). 
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2.3 Tissue collection 
 All rats were sacrificed by decapitation. Trunk blood was collected into K2EDTA coated 
tubes and kept on ice. Organs were excised and wet weight was recorded prior to flash freezing 
in liquid nitrogen. Brain was extracted immediately (generally within 3-5 minutes) and the left 
hemisphere was flash frozen in liquid nitrogen. Right hemispheres of all rats were immersion-
fixed in 10% neutral buffered formalin (Fisher Scientific International) for 48 hours and then 
were transfer to 70% Ethanol before staining. Hippocampus and cerebral cortex were extracted 
from the rest of the right hemispheres and fixed in RNAlater (Ambion, inc. Austin, TX) for RNA 
extraction. 
2.4 Histology 
 All the right hemisphere brain tissues preserved in 10% neutral buffered formalin were 
sent to Histology lab, Division of Human Pathology, Michigan State University for Hematoxylin 
and eosin stain (H&E) staining and Congo red staining.  Nuclei were counter stained by H&E for 
visualizing the morphological changes of the neurons. Congo red staining was performed to 
visualize extracellular amyloid deposition in the hippocampus on the brown Norway rats. All the 
slides were observed under the microscope (Nikon Eclipse 80i). 
2.5 Enzyme-linked Immunosorbent Assay 
 This assay involves a two part process; firstly the whole tissue extraction and running the 
assay. The Colorimetric BetaMark x-42 ELISA kit was purchased from Covance (Princeton, 
New Jersey, USA). All the reagents, standard dilutions, control and samples were reconstituted 
according Covance protocol. The whole brain tissues of all the rats in the four groups; control 
(C), high cholesterol (H), high cholesterol and oil palm phenolics (HP) and high cholesterol and 
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curcurmin (HC) were homogenized individually in TBS with protease inhibitors and EDTA. 
70% formic acid was added to the homogenate, to mix we agitated the tissue by pipetting up and 
down. We spun the mixture of each group for 20 minutes at 350,000 g. The supernatant which 
represents the whole brain extract was retrieved for the assay. The supernatant was stored in -80 ֯ 
C. To start running the assay the sample were removed from -80֯ C and thawed on ice. 300 µL of 
1X wash buffer were added to each well, then dumped out after which the plate is pat dried on 
clean paper towel. On day 1, 50µL of each standard was added to the plate in triplicate. 50µL of 
each sample was added in triplicate as well as 50 µL to each well of diluted HRP detection 
antibody. The plate was then covered with a plate sealer. The plate was mixed on a plate shaker 
for one minute and then incubated overnight at 8 ֯C. On day 2, the plate was removed from the 
refridgerator and the contents are dumped out. The plate was then washed with 300µL of 1X 
wash buffer per well. The buffer was then dumped and the plate pat dried with clean paper towel. 
The plate was washed repeatedly with the 1X wash buffer 4 more times for a total of 5 washes. 
200µL of TMB substrate was added to each well. The plate was then incubated for 50 minutes at 
room temperature in the dark. The optical density of each plate was determined using a Bio-tek 
Elx800 micro-plate reader set at a wavelength of 620nm. The concentration of the unknown 
(β42) was calculated using the standard curve.  
2.6 Statistics 
 All statistical analyses were performed using SPSS 15.0 for Windows® and 
SmartWiewerTM, (SPSS Inc. Chicago, IL). Data were analyzed using one- or two-way ANOVA 
with the age and diet as between-subject factors followed by Tukey post-hoc tests. Comparisons 
between the diets in the same age group were analyzed using student t-test. For MWM test, the 
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trial day was the repeated within-subject factor and diet was the between-subject factors. Results 
are presented as the means ± SEM. 
  
23 
 
 
CHAPTER 3 
RESULTS 
3.1 DIET AND WATER MAZE 
 
We were successful in feeding the rat models isocaloric diets across the control, high cholesterol, 
high cholesterol and OPP, high cholesterol and curcumin groups. There was no significant gain 
or loss of weight during the 23 week period of feeding and weighing of the animal models 
(figure 5 and 6). The Morris water maze experiment revealed longer escape latency time initially 
for the high cholesterol group but this improved from day 3 (figure 7). Subsequently, we 
observed significant improvement in escape latency time when month 1 was compared to month 
5 (figure 8). 
 
Figure 5: Mean dietary Intake per group consumed at week 1 and week 23.   
Results represent mean + SE. 
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Figure 6: Mean body weight of rats per group at week 1 and Week 23. 
 Results represent mean + SE. 
 
Figure 7: Escape Latency times at month 1 of Morris water maze. 
 * P < 0.05 when compared with control group. Statistical analysis ANOVA with Tukey’s procedure was 
used SPSS software  
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Figure 8:  Morris Water Maze.  
Improvement in Escape Latency (EL) using Morris water maze test in the OPP fed group (HP)  from month 1 (M1) to 
month 5 (M5) of the study. 
3.2 HISTOLOGY AND ELISA 
 
 When viewed under the Nikon microscope the H & E stained slides reveal more dead 
neurons and neuronal in the control and high cholesterol group compared to the control, high 
cholesterol +OPP and high cholesterol+ curcumin groups (p<0.05) (figure 9). We also noticed a 
higher concentration of dead neurons in the CA1 zone of the hippocampus. A significant 
decrease in healthy neurons was observed in the high cholesterol group (figure 10). The high 
cholesterol group contained the highest area of beta amyloid plaque deposition (figure 11). 
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Figure 9:   Dead Neurons. 
This figure shows the presence of dead neurons (pyramidal shaped, intensely colored) in the hippocampal 
areas; CA1, CA3 and DG of the animal groups; C= Control, H=High Cholesterol, HP= High Cholesterol+ 
OPP, HC= High Cholesterol+ Curcumin 
The Congo red stained slides detected extracellular plaque formation, predominantly in the high 
cholesterol group as observed through the microscope. Plaque deposition in the control group 
was negligible (figure 12). High cholesterol diet induced plaque was visualized in the high 
cholesterol group, high cholesterol + OPP group and high + curcumin group (figure 13, 14 and 
15).  
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 In addition, the congo red stained slides showed that the high cholesterol group had the 
highest average plaque load (% hippocampus area) compared to other two supplemented high 
cholesterol diet (Figure 16 and 17). ELISA was performed to identify the amyloid peptide and 
quantify the beta amyloid plaque that was observed (Figure 18). 
 
Figure 10: Number of healthy neuron s in the hippocampus 
                    
 
 Figure 11: Sum of the area of individual plaque concentration in each group 
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Figure 12:    Congo Red stained slide of the Control group (C) revealing negligible traces of amyloid 
plaques. 
 
 
Figure 13:   Congo Red stained slide of the High Cholesterol group (H) showing traces of amyloid  
deposition, indicated by the arrows. 
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Figure 14: Congo Red stained slide of the High Cholesterol + OPP group (HF) showing few traces 
of  amyloid deposition, indicated by the arrows. 
   
 
Figure 15:  Congo Red stained slide of High Cholesterol + curcumin group (HC) showing  few  
traces of amyloid plaques, indicated by the arrows. 
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Figure 16:    Amyloid plaque load 
 
 
Figure 17: Average number of plaques. 
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Figure 18:    The concentration of β-amyloid 42 quantified via ELISA 
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CHAPTER 4 
4.1   DISCUSSION 
 This study is part of a broader experiment being conducted by a PhD student focusing on 
the invivo effect of OPP on atherogenic diet induced rat models (figure 19). The goal of my 
study is to show histological evidence of the impact that a diet containing OPP will have on beta 
amyloid deposition in the hippocampus of aged Brown Norway rat model induced by a high fat 
diet. The results of our study is closely linked to that of Tara L Spires et al and West MJ et al 
were it was observed that selective damage seemed domicile in the CA1 zone compared to the 
CA3 zone. In our study dead and degenerated neurons were noticeable in the control and high 
cholesterol only group as depicted by the absorption of the dark blue dye vie H and E staining ; 
which histologically represents a diseased or dead neuron [41][42]. Congo red stain is a 
diagnostic tool for amyloidosis, it functions by binding to amyloid fibrils which can subsequently 
be observed under a microscope [43][44]. Congo red staining enabled visualization of 
extracellular amyloid deposition in the hippocampus. 
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Figure 19: LAYOUT OF STUDY 
 
 
In our study the control group showed minimal presence of amyloid deposition, this should not 
be the case because aging should impact the normal metabolism of beta amyloid peptides. 
Therefore, there should have been some accumulation of beta amyloid plaques in the 
hippocampus in the control group. This is an exception. It is likely that viewing the slides under 
the microscope failed to capture the plaque load in the control group because the ELISA 
conducted revealed plaque load in the control group. The ELISA proved to be a more sensitive 
and specific test due to its ability to reveal the hydrophobic beta amyloid peptide load undetected 
by Congo red staining. It could also be possible that the amyloid plaques observed were strictly 
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due to intake of the high cholesterol diet. Other epidemiology studies have revealed that 
ingestion of diets high in fat and cholesterol can be linked increased cases of dementia. In these 
studies the form of fat responsible for the presentation of AD tended to be saturated in nature 
[45]. Linoleic acid which is a form of omega-6-polyunsaturated fat was not linked to AD. 
Although the mechanism in which high cholesterol  diet  impacts cognitive  function is yet to be 
known, it has been proposed by other extensive research that activation of  protein kinase C and 
phosphorylation of protein F by high unsaturated fat lead to higher memory storage as a result of 
increased synaptic plasticity. In addition other studies have shown that cholesterol lowering 
drugs decreased the deposition of beta amyloid and othe AD related disease states. [46][47]. In 
our study, high fat diet had successfully induced the AD-like pathologies both behaviorally (i.e. 
Learning /memory deficits) and histologically (i.e. Aβ plaque formation in hippocampus). In 
addition, aging might also serve as a factor by accelerating the AD pathology, given the fact that 
all of our rats arrived at 22-24 month of age. So the elevated peripheral hypercholesterolemia and 
a higher liver and brain cholesterol observed by my colleagues working on this project could 
accelerate memory and brain damage, which confirm the opinion that high cholesterol diet is one 
of the risk factors  that cause AD-like brain metabolic changes. In the current study,the aged rats 
amplified the effects of the diet in the model. It can be clearly put that our diet treatment 
effectively created hypercholesterolemia condition in the Brown Norway rat model and this 
effect was synergistically accelerated by aging effect. The test botanical, OPP clearly diminished 
not only the beta amyloid peptides but was neuro-protective since histologically more healthy 
neurons were observed in the rats that ingested this phenolic substance. The results seen in the 
rats fed OPP plus high cholesterol were similar to that of the curcumin fed group which served as 
our positive control. Curcumin was well suited as our positive control since literature has 
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reported its ability to prevent Aß fibril plaque formation and protect the neurons from being 
attacked by Aß oligomers and fibrils [48]. Curcumin has been widely studied for its clinical 
benefits as an anti-inflammatory agent, an anti-amyloidogenic, an antioxidationt and an 
anticarcinogen [49]. In previous studies, curcumin has been successful in suppressing the pro-
apotoptic action of vasoactive peptide endothelin-1 (ET-1) which is increased in the human brain 
tissue presented in AD pathology [50]. It’s mechanism of action facilitating this inhibition of ET-
1 is still being researched. The anti-inflammatory, anti-oxidant and anti-amyloidogenic 
properties of curcumin have also been tested in a study performed in transgenic mice, Tg2576 
that were provided a curcumin diet for 6 months [51]. It was observed that there was a significant 
reduction in IL-1β, GFAP (an astroglia marker), plaque load , soluble and insoluble beta amyloid 
peptides. Based on the aforementioned studies, we utilized curcumin as a positive control to test 
the neuroprotective properties of OPP. There is limited data on the effect of OPP in AD but it has 
been reported to possess anti-diabetic, anti-carcinogenic and antioxidant properties [52]. To test 
for possible cardioprotective effects of OPP, Sambanthamurthi et al. carried out in vitro LDL 
oxidation studies and they found that OPP inhibited the Cu-mediated oxidation of human LDL. It 
was concluded that OPP have an antioxidant protective role against free radical damage, which 
represents a new source of phenolic bioactives [49]. In order to test its neuro-protective effects, 
Leow et al. fed the mice model; BALB/c with an OPP infused diet and then investigated the 
effects of OPP on cognitive and motor functions. It was observed that better cognitive function 
and spatial learning was achieved when tested in a water maze. That study proposed that OPP 
can improve the neuron damage by up-regulating the genes involved in the regulation of the 
neurotrophic factor and meanwhile, down-regulating the genes involved in inflammation [50]. 
The main limitation of this study was the challenges faced with the microscope used to visualize 
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the congo red stained species and the reality that more research needs to be conducted using 
OPP. In addition, it is quite clear that we are yet to conduct transcriptomic analysis on the brains 
and then identify the gene expression changes. This will generate clues to help explain how OPP 
confers these neuro-protective effects. This study was meant to be exploratory rather than 
confirmatory , there are currently no extensive studies to demonstrate the effects of OPP on the 
high fat induced AD animals. 
4.2 Conclusion 
 Data from the histological analysis and ELISA in this study did demonstrate that high fat 
diet induced beta amyloid deposition in the hippocampus. The neurotoxic species, Aβ42, was 
clearly prominent in the high cholesterol group and noticeably reduced in the rats fed high 
cholesterol plus OPP and curcumin respectively. OPP has significant neuro-protective properties 
as it effectively improved the spatial learning abilities of rats on high cholesterol diet. These 
improvements correlate to its neuron protective effect and its ability to lower amyloid load in 
hippocampus. Based on our study results, OPP can improve cognitive impairment, reduce neuron 
loss and decrease beta amyloid deposition in the hippocampus. Findings from this study has 
provided evidence for more research to geared towards investigating genetic regulation pathways 
and other innovative strategies to address the impact of OPP in AD models. It may also be noted 
that since late onset AD accounts for about 87% of this form of dementia, more studies can be 
conducted to investigate the impact of OPP on ApoEε4. 
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ABSTRACT 
HISTOLOGICAL EVIDENCE OF THE EFFECT OF OIL PALM 
PHENOLICS IN ATHEROGENIC DIET INDUCED RAT MODEL OF 
ALZHEIMER’S DISEASE 
by 
KENECHUKWU UCHENNA MONPLAISIR 
August 2016 
Advisor: Dr. Smiti Gupta 
Major: Nutrition and Food Science 
Degree: Master of Science 
BACKGROUND: Alzheimer’s disease (AD) is a neurodegenerative disease with the clinical 
presentation of memory loss and cognitive impairment. Alzheimer's disease pathology is the 
accumulation of beta amyloid plaques and neurofibrillary tangles. 
METHOD: In this study atherogenic diet was used to induce AD in aged Brown Norway rats. 
The rats were assigned to the following four groups fed  isocaloric diets; control group (C ),high 
cholesterol diet (H), high cholesterol + oil palm phenolics group (HP), high cholesterol + 
curcumin group (HC). The impact of oil palm phenolics (OPP) on neuronal health and its effect 
on amyloid deposition was evaluated using histology and ELISA. The cognitive ability of the 
rats were tested using Morris water maze. 
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RESULTS: Our model was successful in facilitating the formation of extracellular beta amyloid 
plaques and causing neuronal loss. Histological findings revealed better neuronal health in the 
group of rats offered OPP in their diets compared to the high cholesterol only fed rats. The 
Morris water maze test showed better learning and cognition in rats fed the OPP diet. 
CONCLUSION: OPP provided neuronal protection and decreased the deposition of beta 
amyloid plaques in the hippocampus of the rats. 
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